Terminated PHASE2 INTERVENTIONAL 2-arm NCT00143819

Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis

Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin

Sponsor: AVVAA World Healthcare Products, Inc.

Interventions Neuroskin Forte Placebo Application

Updated 10 times since 2017 Last updated: Apr 7, 2017 Started: Sep 30, 2005 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

Listed as NCT00143819, this PHASE2 trial focuses on Eczema and Psoriasis and remains terminated or withdrawn. Sponsored by AVVAA World Healthcare Products, Inc., it has been updated 10 times since 2005, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE2
Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2017 — Jun 2018 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Jan 2017 — Jun 2017 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AVVAA World Healthcare Products, Inc.
University of Medicine and Dentistry of New Jersey

Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.